We are thrilled to announce that our corporate partner Constructive Space has raised an incredible £17,288 to support people living with MS.
Mavenclad (cladribine) has been approved as a treatment for people with highly active relapsing MS on the NHS in England and Wales.
The air guitars were out in force last month at a special battle of the bands event in aid of the MS Trust.
Ibudilast slowed down the loss of brain volume in primary and secondary progressive MS by almost one half compared to placebo according to results presented at ECTRIMS 2017.
- Fatty diet and relapse risk
- Clemastine may help repair MS damage
- The MS symptoms that contribute most to perception of health
The annual fundraising dinner and auction organised by city philanthropists, The October Club, has raised £500,000 for our Advanced MS Champions project, which will bring urgently needed care and support to people living with the effects of advanced MS.
Results of a small study suggest that clemastine, a drug used to treat allergies, may repair damage to myelin in the optic nerve of people with MS.
- Salt doesn't cause MS
- Fatigue treated with small electric current
- Taxi discrimination challenged
- Stem cells - the genuine potential and the dodgy clinics
- MS drugs in Northern Ireland
- Disease modifying drugs - early vs escalation trial
- Moves to reclassify pregabalin and gabapentin
- Links between cognition and mobility
- Lemtrada remains effective over five years
- Fall risk and bladder dysfunction
- MS disease activity linked to depression and anxiety